Healthcare Industry News: INSYS Therapeutics
News Release - April 10, 2017
Repros Names Larry Dillaha, M.D., its Permanent President and CEOTHE WOODLANDS, Texas, April 10, 2017 -- (Healthcare Sales & Marketing Network) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the Company’s Board of Directors has appointed Larry Dillaha, M.D., the President and Chief Executive Officer of the Company, effective immediately. Dr. Dillaha has been serving in these capacities on an interim basis since February 1, 2017. Dr. Dillaha has also been named to the Board, filling an existing vacancy.
“Larry is the right person to lead Repros forward as we advance our pipeline and move toward our next stage of growth,” said Patrick Fourteau, Chairman of the Company’s Board. “We are confident that Larry’s fresh perspective, extensive experience and enthusiasm for Repros’ future will be of great value as we face our near-term challenges and set a course for the longer term future.”
Dr. Dillaha was previously the Chief Executive Officer of CavtheRx, an inception stage biotechnology company, and before that the Chief Operating Officer and Chief Medical Officer of New Haven Pharmaceuticals, a specialty pharmaceutical company. He also served as Chief Medical Officer of INSYS Therapeutics, Sciele Pharma and as Medical Director of Sanofi-Sythelabo. Dr. Dillaha received an M.D. degree from the University of Tennessee, Memphis.
About Repros Therapeutics Inc.®
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “believe,” “plan,” “seek,” “could,” “can,” “should” or similar expressions. These statements are based on assumptions that the Company has made in light of the Company’s experience in the industry, as well as the Company’s perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to the Company’s pipeline and plans for growth, and are subject to such risks as are identified in the Company’s most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please visit the Company’s website at http://www.reprosrx.com.
Source: Repros Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.